These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6966024)

  • 21. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
    Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
    Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphonuclear leucocyte fluorescence and cryoglobulin phagocytosis in systemic lupus erythematosus.
    Losito A; Lorusso L
    Clin Exp Immunol; 1979 Mar; 35(3):376-9. PubMed ID: 222518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunologic anomalies in inflammatory diseases of connective tissue in children].
    Popescu V; Arion C; Dragomir D; Bleahu D; Popescu D; Hurduc V; Tiţeica M; Mateescu D; Ilinca D
    Rev Pediatr Obstet Ginecol Pediatr; 1989; 38(2):161-72. PubMed ID: 2511614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunofluorescence of cutaneous vasculitis associated with systemic disease.
    Schroeter AL; Copeman PW; Jordon RE; Sams WM; Winkelmann RK
    Arch Dermatol; 1971 Sep; 104(3):254-9. PubMed ID: 4398554
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapy of neurological disorders in systemic vasculitis.
    Gold R; Fontana A; Zierz S
    Semin Neurol; 2003 Jun; 23(2):207-14. PubMed ID: 12894386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous necrotizing vasculitis and related disorders.
    Gilliam JN; Smiley JD
    Ann Allergy; 1976 Nov; 37(5):328-39. PubMed ID: 11718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitation of complement proteins in rheumatic disease.
    George D; Glass D
    Clin Rheum Dis; 1983 Apr; 9(1):177-98. PubMed ID: 6603322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: a new therapeutic option.
    Yoon KH
    Ann N Y Acad Sci; 2009 Sep; 1173():752-6. PubMed ID: 19758225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vasculitis: current concepts].
    Karsh J; Dorval G; Gilmore N; Osterland CK
    Union Med Can; 1976 Apr; 105(4):514-23. PubMed ID: 11599
    [No Abstract]   [Full Text] [Related]  

  • 30. [Circulating immunocomplexes in patients with various morbid conditions].
    D'Amelio R; Milano CF; Le Moli S; Palmisano L
    Minerva Med; 1979 Dec; 70(57):3901-5. PubMed ID: 160999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble adhesion molecules in pediatric rheumatic diseases.
    Bloom BJ; Miller LC; Blier PR
    J Rheumatol; 2002 Apr; 29(4):832-6. PubMed ID: 11950029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases.
    Salonen EM; Miettinen A; Walle TK; Koskenmies S; Kere J; Julkunen H
    Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
    Dejica D
    Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Systemic autoimmune diseases with neurocutaneous alterations].
    Oliveros-Cid A; Martínez-Vila E; Castillo J
    Rev Neurol; 1997 Sep; 25 Suppl 3():S294-308. PubMed ID: 9273175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Urticarial vasculitis syndrome. A case report and review of the literature].
    Iannello S; Asmundo GO; Cataliotti A; Floridia S; Loreno M; Trovato G; Vintaloro G; Belfiore F
    Minerva Med; 1997 Nov; 88(11):459-67. PubMed ID: 9454098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunopathologic mechanism in some ocular diseases].
    Rogoz S; Avramescu C; Siloşi I; Drackoulogona O; Badea P; State A
    Oftalmologia; 2002; 54(3):51-5. PubMed ID: 12723199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement-mediated solubilization in patients with systemic lupus erythematosus, nephritis or vasculitis.
    Schifferli JA; Morris SM; Dash A; Peters DK
    Clin Exp Immunol; 1981 Dec; 46(3):557-64. PubMed ID: 7337980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous vasculitis and rheumatoid factor positivity as presenting signs of hepatitis C virus-induced mixed cryoglobulinemia.
    Karlsberg PL; Lee WM; Casey DL; Cockerell CJ; Cruz PD
    Arch Dermatol; 1995 Oct; 131(10):1119-23. PubMed ID: 7574826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
    Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
    Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.